| Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) M Herdman, C Gudex, A Lloyd, MF Janssen, P Kind, D Parkin, G Bonsel, ... Quality of life research 20, 1727-1736, 2011 | 7782 | 2011 |
| Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis N Devlin, D Parkin Health economics 13 (5), 437-452, 2004 | 929 | 2004 |
| Aggregate health care expenditures and national income: is health care a luxury good? D Parkin, A McGuire, B Yule Journal of health economics 6 (2), 109-127, 1987 | 566 | 1987 |
| A single European currency for EQ-5D health states: results from a six-country study W Greiner, T Weijnen, M Nieuwenhuizen, S Oppe, X Badia, J Busschbach, ... The European Journal of Health Economics, formerly: HEPAC 4, 222-231, 2003 | 544 | 2003 |
| Economic analysis in healthcare S Morris, N Devlin, D Parkin, A Spencer John Wiley & Sons, 2012 | 535 | 2012 |
| Effect of computerised evidence based guidelines on management of asthma and angina in adults in primary care: cluster randomised controlled trial M Eccles, E McColl, N Steen, N Rousseau, J Grimshaw, D Parkin, ... Bmj 325 (7370), 941, 2002 | 450 | 2002 |
| NICE's cost effectiveness threshold J Appleby, N Devlin, D Parkin Bmj 335 (7616), 358-359, 2007 | 310 | 2007 |
| The influence of cost‐effectiveness and other factors on nice decisions H Dakin, N Devlin, Y Feng, N Rice, P O'neill, D Parkin Health economics 24 (10), 1256-1271, 2015 | 283 | 2015 |
| Assessing the performance of the EQ-VAS in the NHS PROMs programme Y Feng, D Parkin, NJ Devlin Quality of Life Research 23, 977-989, 2014 | 268 | 2014 |
| Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data NJ Devlin, D Parkin, J Browne Health economics 19 (8), 886-905, 2010 | 262 | 2010 |
| Measuring production efficiency of acute hospitals in Scotland, 1991-94: validity issues in data envelopment analysis D Parkin, B Hollingsworth Applied economics 29 (11), 1425-1433, 1997 | 261 | 1997 |
| Is there a case for using visual analogue scale valuations in cost‐utility analysis? D Parkin, N Devlin Health economics 15 (7), 653-664, 2006 | 247 | 2006 |
| Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation R Thomson, D Parkin, M Eccles, M Sudlow, A Robinson The Lancet 355 (9208), 956-962, 2000 | 232 | 2000 |
| Methods for analysing and reporting EQ-5D data N Devlin, D Parkin, B Janssen Springer Nature, 2020 | 201 | 2020 |
| Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life D Parkin, A Jacoby, P McNamee, P Miller, S Thomas, D Bates Journal of Neurology, Neurosurgery & Psychiatry 68 (2), 144-149, 2000 | 167 | 2000 |
| Searching for cost effectiveness thresholds in the NHS J Appleby, N Devlin, D Parkin, M Buxton, K Chalkidou Health policy 91 (3), 239-245, 2009 | 138 | 2009 |
| Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? D Parkin, N Rice, N Devlin Medical Decision Making 30 (5), 556-565, 2010 | 112 | 2010 |
| Relationship between service ecology, special observation and self-harm during acute in-patient care: City-128 study L Bowers, R Whittington, P Nolan, D Parkin, S Curtis, K Bhui, D Hackney, ... The British Journal of Psychiatry 193 (5), 395-401, 2008 | 112 | 2008 |
| Estimating the costs of conflict and containment on adult acute inpatient psychiatric wards C Flood, L Bowers, D Parkin Nursing economics 26 (5), 325, 2008 | 112 | 2008 |
| A cost-utility analysis of interferon beta for multiple sclerosis. D Parkin, P McNamee, A Jacoby, P Miller, S Thomas, D Bates Health technology assessment (Winchester, England) 2 (4), iii-54, 1998 | 108 | 1998 |
